List of Excipients in API vibegron
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing vibegron
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Sumitomo Pharma America Inc | GEMTESA | vibegron | 73336-075 | CELLULOSE, MICROCRYSTALLINE | 2029-04-02 |
| Sumitomo Pharma America Inc | GEMTESA | vibegron | 73336-075 | CROSCARMELLOSE SODIUM | 2029-04-02 |
| Sumitomo Pharma America Inc | GEMTESA | vibegron | 73336-075 | FD&C BLUE NO. 2 ALUMINUM LAKE | 2029-04-02 |
| Sumitomo Pharma America Inc | GEMTESA | vibegron | 73336-075 | FERRIC OXIDE YELLOW | 2029-04-02 |
| Sumitomo Pharma America Inc | GEMTESA | vibegron | 73336-075 | HYDROXYPROPYL CELLULOSE | 2029-04-02 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for vibegron
Excipient focus: CELLULOSE, MICROCRYSTALLINE
vibegron drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Sumitomo Pharma America Inc | vibegron | 73336-075 |
| >Company | >Ingredient | >NDC |
vibegron drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
vibegron drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Sumitomo Pharma America Inc | vibegron | 73336-075 |
| >Company | >Ingredient | >NDC |
vibegron drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 2 ALUMINUM LAKE
vibegron drug variants containing FD&C BLUE NO. 2 ALUMINUM LAKE
| Company | Ingredient | NDC |
|---|---|---|
| Sumitomo Pharma America Inc | vibegron | 73336-075 |
| >Company | >Ingredient | >NDC |
vibegron drug variants not containing FD&C BLUE NO. 2 ALUMINUM LAKE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
vibegron drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Sumitomo Pharma America Inc | vibegron | 73336-075 |
| >Company | >Ingredient | >NDC |
vibegron drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
vibegron drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Sumitomo Pharma America Inc | vibegron | 73336-075 |
| >Company | >Ingredient | >NDC |
vibegron drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
vibegron drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Sumitomo Pharma America Inc | vibegron | 73336-075 |
| >Company | >Ingredient | >NDC |
vibegron drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
vibegron drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Sumitomo Pharma America Inc | vibegron | 73336-075 |
| >Company | >Ingredient | >NDC |
vibegron drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
vibegron drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Sumitomo Pharma America Inc | vibegron | 73336-075 |
| >Company | >Ingredient | >NDC |
vibegron drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
vibegron drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Sumitomo Pharma America Inc | vibegron | 73336-075 |
| >Company | >Ingredient | >NDC |
vibegron drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
vibegron drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Sumitomo Pharma America Inc | vibegron | 73336-075 |
| >Company | >Ingredient | >NDC |
vibegron drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIACETIN
vibegron drug variants containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Sumitomo Pharma America Inc | vibegron | 73336-075 |
| >Company | >Ingredient | >NDC |
vibegron drug variants not containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch